The Ministry of Health and Family Welfare is preparing to make significant changes to regulations concerning imported medicines. The Ministry has released a draft amendment to Rule 31 of the Drugs Rules, 1945, inviting suggestions and objections from the general public and stakeholders. The objective of this proposal is to promote ‘Ease of Doing Business’ in the pharmaceutical sector and ensure the availability of quality medicines for patients.
A Remaining Shelf Life of 12 Months Will Suffice
The draft, issued via a gazette notification on June 22, proposes altering the current requirement that imported medicines must have more than 60 percent of their shelf life remaining. Under the new proposal, a remaining shelf life of at least 12 months at the time of import will be sufficient. It is worth noting that the shelf life of a medicine refers to the period during which it remains safe and fully effective; this period extends from the date of manufacture to the expiry date printed on the product.
However, the Ministry has clarified that existing rules will continue to apply to biological products and radiopharmaceuticals. In other words, the requirement for more than 60 percent remaining shelf life at the time of import will remain unchanged for these special categories of medicines, owing to their unique nature and public health considerations.
What Are the Benefits?
The Ministry states that this amendment will make the pharmaceutical supply chain more efficient. Ensuring that imported medicines have at least 12 months of remaining shelf life upon arrival provides adequate time to distribute them to the market and make them available to patients. This ensures that patients continue to receive quality medicines with a usable shelf life. The government believes this change will also reduce unnecessary wastage of medicines, as the current strict shelf-life regulations often lead to losses during storage and distribution. Consequently, supply management will improve, costs will decrease, and the availability of essential medicines in the country will be strengthened. The Ministry of Health has also clarified that this proposal pertains solely to the condition regarding residual shelf life applicable at the time of import. All other regulations concerning the quality, safety, and efficacy of drugs under the Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945, will continue to apply as before. The Ministry has invited suggestions and objections regarding this draft from all stakeholders. Interested parties may submit their suggestions via the official email within the stipulated timeframe.
